Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby N Trahair

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|September 2, 2021
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcomaVinod Vijay Subhash, Libby Huang, Alvin Kamili, et al.
British Journal of Haematology|December 2, 2017
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in childrenRosemary Sutton, Nicola C Venn, Tamara Law, et al.
Haematologica|February 11, 2021
Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemiaMarion K Mateos, Glenn M Marshall, Pasquale M Barbaro, et al.
Journal of Adolescent and Young Adult Oncology|June 27, 2023
Guidelines for Caring for the Social Well-Being of Adolescents and Young Adults with Cancer in AustraliaClarissa E Schilstra, Ursula M Sansom-Daly, Sarah J Ellis, et al.
BMC Cancer|September 15, 2022
Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemiaClarissa E Schilstra, Karen McCleary, Joanna E Fardell, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 13, 2026
Strategic consensus on the clinical translation of advanced therapies in paediatric rare neurological disordersNatalie Y Lim, Christian E Meagher, Ann Bye, et al.
Pediatric Blood & Cancer|February 27, 2021
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomabRosemary Sutton, Luciano Dalla Pozza, Seong Lin Khaw, et al.
Science Advances|November 28, 2025
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastomaJeremy Z R Han, Monica Phimmachanh, Jordan F Hastings, et al.
Molecular Cancer|July 5, 2024
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patientsLenka Hovorkova, Lucie Winkowska, Justina Skorepova, et al.
Journal of Personalized Medicine|July 29, 2023
Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine TrialRebecca Daly, Kate Hetherington, Emily Hazell, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|September 2, 2021
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcomaVinod Vijay Subhash, Libby Huang, Alvin Kamili, et al.
British Journal of Haematology|December 2, 2017
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in childrenRosemary Sutton, Nicola C Venn, Tamara Law, et al.
Haematologica|February 11, 2021
Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemiaMarion K Mateos, Glenn M Marshall, Pasquale M Barbaro, et al.
Journal of Adolescent and Young Adult Oncology|June 27, 2023
Guidelines for Caring for the Social Well-Being of Adolescents and Young Adults with Cancer in AustraliaClarissa E Schilstra, Ursula M Sansom-Daly, Sarah J Ellis, et al.
BMC Cancer|September 15, 2022
Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemiaClarissa E Schilstra, Karen McCleary, Joanna E Fardell, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 13, 2026
Strategic consensus on the clinical translation of advanced therapies in paediatric rare neurological disordersNatalie Y Lim, Christian E Meagher, Ann Bye, et al.
Pediatric Blood & Cancer|February 27, 2021
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomabRosemary Sutton, Luciano Dalla Pozza, Seong Lin Khaw, et al.
Science Advances|November 28, 2025
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastomaJeremy Z R Han, Monica Phimmachanh, Jordan F Hastings, et al.
Molecular Cancer|July 5, 2024
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patientsLenka Hovorkova, Lucie Winkowska, Justina Skorepova, et al.
Journal of Personalized Medicine|July 29, 2023
Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine TrialRebecca Daly, Kate Hetherington, Emily Hazell, et al.
Pageof 6